(IN BRIEF) Evonik is investing more than CAD 150 million, or approximately EUR 93 million, in a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada, supported by up to CAD 68 million, or around EUR … Read the full press release
Posted in Business, Chemicals, Germany, Government, Healthcare, Industrial, Investment, Pharma & Biotech, Science, Technology
Tagged 2034, adjuvant supply, advanced medicines, biotech ecosystem, Birmingham Alabama, British Columbia, CAD 150 million, CAD 68 million, Cambridge Innovation Satellite, CANADA, Canada Economic Development for Quebec Regions, Canadian federal government, CDMO services, clinical manufacturing, commercial process scale-up, commercial scale, Custom Solutions, Dossenheim, drug product manufacturing, end of 2029 production, equipment engineering, EUR 42 million, EUR 93 million, Evonik, Evonik Expands Lipid-Based Drug Delivery Capacity With New Vancouver GMP Facility, Evonik Health Care, Evonik Invests CAD 150 Million in Vancouver LNP Manufacturing Expansion, Evonik Vancouver Laboratories, formulation development, formulation research, Germany, GMP manufacturing facility, good manufacturing practice, Greater Boston, Greater Vancouver, Guido Skudlarek, Hanau, highly skilled jobs, Lafayette Indiana, Lauren Kjeldsen, life sciences innovation, lipid chemistry, lipid nanoparticles, lipid-based drug delivery, liposomal delivery systems, LNP, Mélanie Joly, microbiological testing, mRNA, New Evonik GMP Facility to Support Lipid Nanoparticle Drug Development and Manufacturing, Northern Lipids, nucleic acid therapeutics, parenteral drugs, pharmaceutical manufacturing, process engineering, QC, quality control, regulatory know-how, sterile manufacturing, Strategic Response Fund, therapeutics, Tippecanoe Labs, Transferra Nanosciences, University of British Columbia, USD 2.7 billion market forecast, vaccines, Vancouver
(IN BRIEF) Evonik is now offering customers cradle-to-gate Life Cycle Assessment (LCA) data for selected EUDRAGIT® functional polymers, using its TÜV-certified LCA methodology to support pharmaceutical companies with transparent environmental data for Scope 3 emissions reporting. The data is currently … Read the full press release
Posted in Business, Chemicals, Environment, Healthcare, Industrial, Pharma & Biotech, Science, Technology
Tagged 2030 sustainability targets, climate neutrality, coatings, cradle-to-gate assessment, Custom Solutions, Darmstadt, data-driven decisions, delayed release, Dr Jürgen Krauter, drug delivery, emissions reporting, energy use, environmental footprint, environmental transparency, ESG requirements, Essen, EUDRAGIT, EUDRAGIT L 100-55, EUDRAGIT L 30 D-55, EUDRAGIT® L 100-55 Shows 6 Percent Product Carbon Footprint Reduction, Evonik, Evonik Expands Sustainability Transparency for EUDRAGIT® Functional Polymers, Evonik Health Care, Evonik Industries AG, Evonik Offers Cradle-to-Gate LCA Data for Pharmaceutical Excipients, Functional Polymers, Germany, healthcare sustainability, hot melt extrusion, immediate release, Janusz Berger, LCA data, life cycle assessment, Muhammad Irfan, Next Generation Solutions, Oral Drug Delivery Solutions, PCF, pharmaceutical excipients, pharmaceutical processes, pharmaceutical products, pharmaceutical value chain, polymethacrylates, poorly soluble drug substances, process efficiency, product carbon footprint, renewable electricity, Scope 1 emissions, scope 2 emissions, Scope 3 emissions, solubility enhancement, spray drying, spray drying system, surface treatments, sustainability strategy, sustained release, Thilo Krapfl, TRANSPORT, TÜV-certified LCA methodology
(IN BRIEF) Brenntag Pharma has signed a strategic partnership with Evonik REXIM for the exclusive distribution of REXIM® GMP-grade amino acids across most of Europe. The agreement took effect on 1 July 2026 and covers regions including DACH, the UK, … Read the full press release
Posted in Business, Chemicals, Germany, Healthcare, International Trade, Pharma & Biotech
Tagged active pharmaceutical ingredients, APIs, Benelux, bioconversion, biopharma, biopharmaceutical manufacturing, Brenntag, Brenntag and Evonik Build Stronger European Supply Network for GMP-Grade Amino Acids, Brenntag Expands API and Biopharma Offering With REXIM® Amino Acids Agreement, Brenntag Pharma, cell culture media, Central and Eastern Europe, DACH, Europe, Evonik, Evonik Health Care, Evonik REXIM, excipients, fermentation, France, GMP amino acids, Israel, Joakim Rehné, life sciences, Market development, Medical Nutrition, pharmaceutical grade amino acids, pharmaceutical ingredients, regulatory know-how, REXIM, Scandinavia, Strategic Partnership Gives Brenntag Wider Role in Pharmaceutical Amino Acid Distribution, Supply Security, synthetic manufacturing, technical support, Thomas Hermann, Turkey, United Kingdom
(IN BRIEF) Evonik is selling selected production assets for pharmaceutical ingredients at its Hanau site in Germany to the ProChem Group, with the transaction expected to close on 19 June 2026. The divestment supports Evonik Health Care’s strategy of streamlining … Read the full press release
Posted in Business, Chemicals, European Union, France, Germany, Healthcare, Industrial, Pharma & Biotech, Science, Technology
Tagged active pharmaceutical ingredients, advanced pharmaceutical lipids, amino acids, analytical testing, APIs, asset streamlining, CDMO services, cell-culture ingredients, contract manufacturing, cosmetics ingredients, distillation, Dr Jürgen Krauter, drug delivery technologies, drying, Essen, Evonik, Evonik Advances Health Care Growth Strategy Through Hanau Production Asset Transfer, Evonik Health Care, Evonik Sells Hanau Pharmaceutical Ingredient Production Assets to ProChem Group, Evonik Streamlines Health Care Footprint with Sale of Selected Hanau Assets to ProChem, extraction, food additives, France, gene delivery, Gerhard Jakobi, Germany, GMP facility, GMP-compliant production, grinding, Guido Skudlarek, Ham, Hanau, healthcare portfolio, injectable drug delivery, Intermediates, Janusz Berger, Jochen Pohl, Jörg Blumhoff, Kerstin Oberhaus, keto acids, mixing, mRNA delivery, oral drug delivery, packaging, pharmaceutical customers, pharmaceutical ingredients, pharmaceutical lipids, pharmaceutical-grade products, precision biosolutions, ProChem Acquires Evonik GMP Production Facilities for Pharmaceutical Ingredients in Hanau, ProChem GmbH, ProChem Group, ProChem InnoTec GmbH, production assets, regulatory-compliant solutions, REXIM, RNA therapeutics, sieving, specialty chemicals, synthesis, Thomas Hermann, Wuming
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?